| Nome |
# |
|
Personalized in vitro and in vivo cancer models to guide precision medicine, file e3835193-a4b8-72ef-e053-3705fe0ad821
|
630
|
|
Hit and go CAS9 delivered through a lentiviral based self-limiting circuit, file e3835193-fccf-72ef-e053-3705fe0ad821
|
374
|
|
Inherited determinants of early recurrent somatic mutations in prostate cancer, file e3835194-019f-72ef-e053-3705fe0ad821
|
357
|
|
Next-generation rapid autopsies enable tumor evolution tracking and generation of preclinical models, file e3835198-fec5-72ef-e053-3705fe0ad821
|
280
|
|
EthSEQ: ethnicity annotation from whole exome sequencing data, file e3835193-a46f-72ef-e053-3705fe0ad821
|
232
|
|
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer, file e3835193-07a9-72ef-e053-3705fe0ad821
|
215
|
|
TPES: Tumor Purity Estimation from SNVs, file e3835195-d5cf-72ef-e053-3705fe0ad821
|
212
|
|
Mutation–selection balance and compensatory mechanisms in tumour evolution, file e3835198-d830-72ef-e053-3705fe0ad821
|
202
|
|
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer, file e3835196-534a-72ef-e053-3705fe0ad821
|
197
|
|
Ultrasensitive detection of cancer biomarkers by nickel-based isolation of polydisperse extracellular vesicles from blood, file e3835195-d89c-72ef-e053-3705fe0ad821
|
177
|
|
Patient derived organoids to model rare prostate cancer phenotypes, file e3835195-fa19-72ef-e053-3705fe0ad821
|
172
|
|
Genomic correlates to the newly proposed grading prognostic groups for prostate cancer, file e3835193-42fe-72ef-e053-3705fe0ad821
|
171
|
|
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study, file e3835193-b004-72ef-e053-3705fe0ad821
|
168
|
|
PaCBAM: Fast and scalable processing of whole exome and targeted sequencing data, file e3835196-5348-72ef-e053-3705fe0ad821
|
121
|
|
Past, Current, and Future Strategies to Target ERG Fusion-Positive Prostate Cancer, file e3835199-d383-72ef-e053-3705fe0ad821
|
112
|
|
ASEQ: Fast allele-specific studies from next-generation sequencing data, file e3835193-4d8e-72ef-e053-3705fe0ad821
|
109
|
|
The long tail of oncogenic drivers in prostate cancer, file e3835198-fec7-72ef-e053-3705fe0ad821
|
101
|
|
Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity, file e3835199-0779-72ef-e053-3705fe0ad821
|
101
|
|
N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer, file e3835193-4856-72ef-e053-3705fe0ad821
|
97
|
|
Core Biopsies from Prostate Cancer Patients in Active Surveillance Protocols Harbor PTEN and MYC Alterations, file e3835196-3d28-72ef-e053-3705fe0ad821
|
93
|
|
Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer, file e3835197-13f8-72ef-e053-3705fe0ad821
|
88
|
|
A highly specific SpCas9 variant is identified by in vivo screening in yeast, file e3835198-7935-72ef-e053-3705fe0ad821
|
88
|
|
Defining order and timing of mutations during cancer progression: The TO-DAG probabilistic graphical model, file e3835193-4736-72ef-e053-3705fe0ad821
|
85
|
|
Circulating RNAs in prostate cancer patients, file e3835199-b470-72ef-e053-3705fe0ad821
|
83
|
|
Tumor purity quantification by clonal DNA methylation signatures, file e3835198-be09-72ef-e053-3705fe0ad821
|
81
|
|
Ploidy- and Purity-Adjusted Allele-Specific DNA Analysis Using CLONETv2, file e3835199-0777-72ef-e053-3705fe0ad821
|
78
|
|
Ancestry-specific predisposing germline variants in cancer, file e3835197-1ca7-72ef-e053-3705fe0ad821
|
75
|
|
Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer, file e3835199-51be-72ef-e053-3705fe0ad821
|
74
|
|
A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth, file e3835197-e1c7-72ef-e053-3705fe0ad821
|
73
|
|
Genomic correlates of clinical outcome in advanced prostate cancer, file e3835195-d2d8-72ef-e053-3705fe0ad821
|
72
|
|
Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes, file e3835197-437c-72ef-e053-3705fe0ad821
|
71
|
|
Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies, file e3835199-87c0-72ef-e053-3705fe0ad821
|
66
|
|
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers, file e3835198-9020-72ef-e053-3705fe0ad821
|
61
|
|
RB1 heterogeneity in advanced metastatic castration-resistant prostate cancer, file e3835198-96c9-72ef-e053-3705fe0ad821
|
57
|
|
Therapy considerations in neuroendocrine prostate cancer: What next?, file e3835199-e64f-72ef-e053-3705fe0ad821
|
52
|
|
Analytical protocol to identify local ancestry-associated molecular features in cancer, file e3835198-df86-72ef-e053-3705fe0ad821
|
42
|
|
Fast mutual exclusivity algorithm nominates potential synthetic lethal gene pairs through brute force matrix product computations, file e3835199-9d31-72ef-e053-3705fe0ad821
|
34
|
|
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer, file e3835198-a493-72ef-e053-3705fe0ad821
|
30
|
|
Mutation–selection balance and compensatory mechanisms in tumour evolution, file e3835198-fec9-72ef-e053-3705fe0ad821
|
26
|
|
Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer, file e3835199-e64b-72ef-e053-3705fe0ad821
|
24
|
|
High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients, file e3835194-f887-72ef-e053-3705fe0ad821
|
23
|
|
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer, file e3835198-8851-72ef-e053-3705fe0ad821
|
21
|
|
Charting differentially methylated regions in cancer with Rocker-meth, file e3835199-bdcc-72ef-e053-3705fe0ad821
|
18
|
|
Ploidy- and Purity-Adjusted Allele-Specific DNA Analysis Using CLONETv2, file e3835198-dfd4-72ef-e053-3705fe0ad821
|
16
|
|
Clonal evolution of chemotherapy-resistant urothelial carcinoma, file e3835198-956e-72ef-e053-3705fe0ad821
|
15
|
|
Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations, file e3835199-5945-72ef-e053-3705fe0ad821
|
10
|
|
Clonal evolution of chemotherapy-resistant urothelial carcinoma, file e3835193-4cf4-72ef-e053-3705fe0ad821
|
7
|
|
ETS-related gene (ERG) undermines genome stability in mouse prostate progenitors via Gsk3β dependent Nkx3.1 degradation, file 1266738d-5c17-4ae7-894e-0ee8441bd1d4
|
6
|
|
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer, file e3835193-42f9-72ef-e053-3705fe0ad821
|
6
|
|
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer, file e3835193-a3ca-72ef-e053-3705fe0ad821
|
6
|
|
RB1 heterogeneity in advanced metastatic castration-resistant prostate cancer, file e3835196-3d24-72ef-e053-3705fe0ad821
|
6
|
|
A highly specific SpCas9 variant is identified by in vivo screening in yeast, file e3835194-695a-72ef-e053-3705fe0ad821
|
5
|
|
Exome sequencing of African-American prostate cancer reveals loss-of-function ERF mutations, file e3835198-3981-72ef-e053-3705fe0ad821
|
5
|
|
Inherited variant in NFκB‐1 promoter is associated with increased risk of IBD in an Algerian population and modulates SOX9 binding, file e3835196-e57f-72ef-e053-3705fe0ad821
|
4
|
|
Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies, file e3835199-85a6-72ef-e053-3705fe0ad821
|
4
|
|
Plasma AR and abiraterone-resistant prostate cancer, file e3835193-582e-72ef-e053-3705fe0ad821
|
3
|
|
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response, file e3835194-f8d3-72ef-e053-3705fe0ad821
|
3
|
|
ABEMUS: platform specific and data informed detection of somatic SNVs in cfDNA, file e3835196-5aec-72ef-e053-3705fe0ad821
|
3
|
|
Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer, file e3835197-1f96-72ef-e053-3705fe0ad821
|
3
|
|
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers, file e3835198-3989-72ef-e053-3705fe0ad821
|
3
|
|
Prostate cancer: Intrapatient heterogeneity in prostate cancer, file e3835193-42fb-72ef-e053-3705fe0ad821
|
2
|
|
Role of non-coding sequence variants in cancer, file e3835193-45af-72ef-e053-3705fe0ad821
|
2
|
|
High-throughput sequencing of two populations of extracellular vesicles provides an mRNA signature that can be detected in the circulation of breast cancer patients, file e3835193-536c-72ef-e053-3705fe0ad821
|
2
|
|
Second Generation Imaging of Nuclear/Cytoplasmic HIV-1 Complexes., file e3835192-92c7-72ef-e053-3705fe0ad821
|
1
|
|
Voices of biotech, file e3835193-4302-72ef-e053-3705fe0ad821
|
1
|
|
Integrative clinical genomics of advanced prostate cancer, file e3835193-46e3-72ef-e053-3705fe0ad821
|
1
|
|
SPOP mutation leads to genomic instability in prostate cancer, file e3835193-4acc-72ef-e053-3705fe0ad821
|
1
|
|
In-silico identification and functional validation of allele-dependent AR enhancers, file e3835193-4d0f-72ef-e053-3705fe0ad821
|
1
|
|
The Molecular Taxonomy of Primary Prostate Cancer, file e3835193-53a7-72ef-e053-3705fe0ad821
|
1
|
|
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer, file e3835196-3d2a-72ef-e053-3705fe0ad821
|
1
|
| Totale |
5.561 |